New Teva CEO shakes up structure and executive ranks as major layoffs loom

Fierce Pharma --------- New Teva CEO Kåre Schultz is getting down to business—and quickly. Monday, the troubled Israeli drugmaker unveiled a new structure and changes to its leadership team, and it promised its restructuring plan would arrive earlier than expected, too. The company will put its generics and specialty products together under one commercial roof, with segments in North America, Europe and Growth Markets. That move will put Rob Koremans, CEO of Teva’s global specialty drugs, and Dipankar Bhattacharjee, Teva’s generics chief, out of a job. Generic and specialty R&D will be pushed together as well, cueing the departure of CSO Michael Hayden. To learn more click on the picture below to read the article.